ADAPT Naproxen Signal “Not Sufficiently Compelling” To Halt Trial – Speaker
This article was originally published in The Tan Sheet
Executive Summary
The halting of the NIH-sponsored ADAPT trial, which suggested that naproxen may be linked to an elevated cardiovascular risk, was due more to external factors and safety concerns surrounding the COX-2 class than the study data themselves